15 December 2009
New Release Includes Functionality for VMAT Planning and Model Based Segmentation for Clinical Use
February 7 - 11 2010 - Florence, Italy
September 27 2004
Veenendaal, the Netherlands - The Image-Guided Therapy QA Center (ITC, http://itc.wustl.edu) at Washington University School of Medicine in St. Louis, Missouri, has approved the latest version of Nucletron's PLATO Brachytherapy Planning System (BPS) as the first system compliant with the Advanced Technology QA Consortium (ATC) protocol for submission of HDR brachytherapy plans. This approval provides users of PLATO BPS with the ability to participate in RTOG and other cooperative-group clinical trials that require digital data submission. The ATC facilitates the conduct of National Cancer Institute (NCI) sponsored advanced technology radiation therapy clinical trials that require data submissions while maintaining patient confidentiality. This effort includes radiation therapy quality assurance, image and radiation therapy digital data management, and clinical research and developmental efforts. Drs. James Purdy and Walter Bosch of the Image-Guided Therapy QA Center said, “The ITC is delighted to recognize the efforts of Nucletron and the availability of the PLATO BPS planning system for clinical trials involving HDR Brachytherapy. We would like to express our appreciation in advancing these studies.” “This development will facilitate new brachytherapy studies that were previously inhibited by the availability of clinical data at the ITC,” states Tim Bateman, Segment Manager for treatment planning systems at Nucletron. “We are pleased to have made this contribution to enable participation in new studies by the many users of Nucletron remote afterloading brachytherapy systems.” High dose rate brachytherapy treatment plans generated by PLATO BPS can be exported from the treatment planning system and be submitted to the ITC using the DICOM exchange format. The export from the treatment planning system anonymizes patient data. Once received by ITC, the plans can be included in advanced technology clinical trials that have been opened by the RTOG and other cooperative groups. Data that has been included can then be reviewed using a web based Remote Review Tool, that is made available by ITC for clinical trial quality assurance. About Nucletron B.V. Nucletron is a global leader in the development, manufacture, sales, service and support of the world’s most innovative products for cancer treatment, with particular expertise in treatment planning systems, brachytherapy, simulation, integrated software solutions for oncology, and comprehensive support and professional education and services. The company has over 20 offices worldwide, including its corporate headquarters in Veenendaal, The Netherlands. For more information on Nucletron, please visit: http://www.nucletron.com/. Nucletron B.V. is a subsidiary of Delft Instruments N.V. Delft Instruments is the holding company if an international group of companies, which hold a leading position in their respective markets with high quality, high technology products and services. Delft Instruments employs some 1,200 people and reported net profit of EUR 10.4 million on turnover of EUR 237 million in 2003. For more information on Delft Instruments, visit: http://www.delftinstruments.com/
For further information: